Krill Oil Inhibits NLRP3 Inflammasome Activation in the Prevention of the Pathological Injuries of Diabetic Cardiomyopathy

Nutrients. 2022 Jan 15;14(2):368. doi: 10.3390/nu14020368.

Abstract

Diabetic cardiomyopathy (DCM) is a common complication of diabetes mellitus (DM), resulting in high mortality. Myocardial fibrosis, cardiomyocyte apoptosis and inflammatory cell infiltration are hallmarks of DCM, leading to cardiac dysfunction. To date, few effective approaches have been developed for the intervention of DCM. In the present study, we investigate the effect of krill oil (KO) on the prevention of DCM using a mouse model of DM induced by streptozotocin and a high-fat diet. The diabetic mice developed pathological features, including cardiac fibrosis, apoptosis and inflammatory cell infiltration, the effects of which were remarkably prevented by KO. Mechanistically, KO reversed the DM-induced cardiac expression of profibrotic and proinflammatory genes and attenuated DM-enhanced cardiac oxidative stress. Notably, KO exhibited a potent inhibitory effect on NLR family pyrin domain containing 3 (NLRP3) inflammasome that plays an important role in DCM. Further investigation showed that KO significantly upregulated the expression of Sirtuin 3 (SIRT3) and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), which are negative regulators of NLRP3. The present study reports for the first time the preventive effect of KO on the pathological injuries of DCM, providing SIRT3, PGC-1α and NLRP3 as molecular targets of KO. This work suggests that KO supplementation may be a viable approach in clinical prevention of DCM.

Keywords: NLRP3 inflammasome; diabetes; diabetic cardiomyopathy; krill oil.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetic Cardiomyopathies / metabolism
  • Diabetic Cardiomyopathies / prevention & control*
  • Diet, High-Fat / adverse effects
  • Euphausiacea / chemistry*
  • Fibrosis / drug therapy
  • Humans
  • Inflammasomes / metabolism*
  • Inflammation / drug therapy
  • Mice
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism*
  • Oils / pharmacology*
  • Oxidative Stress
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / metabolism
  • Sirtuin 3 / metabolism
  • Streptozocin / adverse effects

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Oils
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Streptozocin
  • Sirtuin 3